Price caps to keep Abbott’s Xience Sierra off the Indian market

Abbott (NYSE:ABT) reportedly won’t introduce its next-generation drug-eluting stent, the Xience Sierra, to the Indian market due to price caps there.

The everolimus-eluting coronary stent, which won CE Mark approval in the European Union this week, is designed to allow cardiologists to treat the complex lesions that make up roughly 70% of cases. It offers a thinner profile, increased flexibility, longer lengths and smaller diameters than previous stents.

Get the full story at our sister site, Drug Delivery Business News.

The post Price caps to keep Abbott’s Xience Sierra off the Indian market appeared first on MassDevice.

from MassDevice http://ift.tt/2AiahyK